Abivax (ABVX) Total Non-Current Liabilities (2021 - 2026)

Abivax's Total Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $64.8 million for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities fell 9.18% year-over-year to $64.8 million in Q1 2026; TTM through Mar 2026 was $64.8 million, a 9.18% decrease from a year earlier, with the FY2025 full-year figure at $77.0 million, up 0.65% from the prior year.
• Total Non-Current Liabilities fell to $64.8 million in Q1 2026 per ABVX's latest filing, from $77.0 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $84.1 million in Q2 2024 and bottomed at $17.2 million in Q4 2022.
• The 5-year median for Total Non-Current Liabilities is $71.3 million (2025), against an average of $63.2 million.
• Across the five-year window, Total Non-Current Liabilities plunged 70.48% in 2022 and jumped 151.96% in 2023, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $17.2 million in 2022, then soared by 151.96% to $43.4 million in 2023, then soared by 73.86% to $75.5 million in 2024, then increased by 1.95% to $77.0 million in 2025, then slipped by 15.85% to $64.8 million in 2026.
• Per Business Quant, the three latest ABVX Total Non-Current Liabilities figures stand at $64.8 million (Q1 2026), $77.0 million (Q4 2025), and $72.5 million (Q3 2025).